[Clinical trial of a novel spasmolytic, pramiverine, and its influence in colitis (author's transl].
In a double blind comparison of 4,4-diphenyl-N-isopropyl-cyclohexylamin-hydrochloride (pramiverine, Sistalgin) with placebo 51 patients with parasitis and bacterial colitis and enterocolitis as well as mixed forms of both were evaluated. The antiparasitic and antibacterial basic therapy was standardised in both groups. In the 27 patients treated with pramiverine the regression of the colitis syndrome starting within a few days was evaluated as excellent to good in 21 patients. In the placebo group similar improvements were observed only in 9 patients out of a total of 24. The good tolerance as compared to other spasmolytics should be equally emphasised as well as the slight inhibition of gastric secretion under prolonged therapy.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy; D001559:Benzhydryl Compounds / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D003092:Colitis / Q000188:drug therapy*; D003514:Cyclohexylamines / Q000627:therapeutic use*; D004761:Enterocolitis, Pseudomembranous / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010272:Parasitic Diseases / Q000188:drug therapy; D010276:Parasympatholytics / Q000627:therapeutic use*; D010919:Placebos
D001559:Benzhydryl Compounds; D003514:Cyclohexylamines; D010276:Parasympatholytics; D010919:Placebos
Prüfung eines neuen Spasmolytikums, Pramiverin, in seiner Wirkung auf die Kolitis